NCAM1 and COVID-19: Subset analysis on circulating CD103+CD56+ NK cells further showed that COVID-19 patients had increased proportions of CD49d+CD103+, CD69+CD103+, and CD69+CD49d+CD103+ NK cells (Fig 3D).